Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Low uric acid predicts severe outcomes in neuronal surface antibody-mediated autoimmune encephalitis.

Created on 19 Jul 2026

Authors

Ying-Zhe Shao, Ning Zhao, Qiu-Xia Zhang, Lin-Jie Zhang, Li Yang

Published in

BMC neurology. Jul 18, 2026. Epub Jul 18, 2026.

Abstract

Autoimmune encephalitis (AE) mediated by neuronal surface antibodies is a severe neuroinflammatory disorder with heterogeneous clinical manifestations. Early identification of patients at risk for severe outcomes, such as intensive care unit (ICU) admission, remains a challenge. Uric acid (UA), known for its dual role in inflammation as both a danger-associated molecular pattern (DAMP) and an antioxidant, has been implicated in various autoimmune diseases, but its prognostic significance in AE has not been systematically explored.
This retrospective study enrolled 90 patients with neuronal surface antibody-positive AE. Serum UA levels were measured at admission, and clinical outcomes, including Clinical Assessment Scale for Autoimmune Encephalitis (CASE), discharge modified Rankin Scale (mRS) and ICU admission were analyzed. Statistical methods included Spearman correlation, logistic regression, and receiver operating characteristic (ROC) curve analysis to evaluate predictive value of UA.
Patients requiring ICU admission had significantly lower UA levels (median 193.0 vs. 250.0 µmol/L, p = 0.008). UA negatively correlated with CASE scores (r = -0.237, p = 0.024) and discharge mRS (r = -0.267, p = 0.011). Logistic analysis identified UA as a potential adjunct biomarker of ICU admission (yes/no) (OR = 0.985, 95%CI:0.971-1.000, p = 0.044), with an optimal cutoff of 213.5 µmol/L (AUC = 0.703, sensitivity 63.9%, specificity 77.8%). Patients with UA < 213.5 µmol/L were older and had higher CASE scores and worse functional outcomes (p < 0.05).
Decreased serum UA at admission is associated with increased risk of ICU admission in neuronal surface antibody-mediated AE, and correlate with a more severe disease severity and poorer functional outcomes, suggesting its potential as a prognostic biomarker, possibly reflecting its neuroprotective role.

PMID:
42471592
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement